ClinicalTrials.gg
CompletedNCT00151515Updated Sep 30, 2016

A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss

A Phase 3 interventional study of minoxidil in Androgenetic Alopecia, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide. Completed at 15 sites in United States. Open to male participants aged 15 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-30.

Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide (formerly part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
15 Years to 49 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing minoxidil in Alopecia — 10 open to participants now, 12 under way, 3 of them phase 3. Minoxidil · Alopecia.

Enrollment
3rd of 31
352 · median 60
Started
2003
the only one that year
Phase 3
8 of 31
2 open now
Registered
1st of 31
by date

Among the 31 studies testing minoxidil in Alopecia, this one is the 3rd largest by enrollment, is the only one that started in 2003, is one of 8 in phase 3, and was the 1st registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

10 of the 31 studies testing minoxidil in Alopecia are open now, in 5 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About minoxidil

Minoxidil: first FDA approval 1979 (LONITEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 15 Years to 49 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing minoxidil in Alopecia, or all of them as a file.
02

Study summary

The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss. The secondary purpose is to evaluate the safety of a topical 5% minoxidil formulation in males when used twice daily for the treatment of pattern hair loss and to obtain the safety data on the investigational product when used twice daily for up to one year.

Read the detailed description

Male subjects with androgenetic alopecia were enrolled in this fourteen-center trial. Subjects were randomized to use either 5% minoxidil or placebo foam twice daily for 16 weeks. A total of 143 subjects continued use of the 5% minoxidil foam for 8 to 12 months in an open-label phase to obtain safety data on 5% minoxidil topical foam when used twice daily for up to one year.

The 5% minoxidil foam was shown to be effective in the treatment of male androgenetic alopecia in a 16 week trial. It was statistically significantly superior to placebo foam in the primary efficacy measure of mean change in the non-vellus hair count in the target region between Baseline and Week 16, and the subject rating assessed an overall improvement from Baseline.

The efficacy of 5% minoxidil compared to placebo was confirmed by the secondary efficacy endpoints of scores from the expert panel review of hair regrowth when comparing photographs obtained at Baseline with photographs obtained at Week 16, as well as the percent change from Baseline in non-vellus hair counts within a pre-specified area of clipped hair.

The 5% minoxidil foam formulation was well tolerated, the incidence of adverse events was similar between groups, and no safety concerns were raised based on clinical laboratory test results, vital signs or scalp irritation scores.

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

Keywords

  • Alopecia, Balding
04

Who can participate

Ages eligible
15 Years to 49 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • presence of androgenetic alopecia with vertex pattern IIIv, IV, or V on the Norwood Hamilton Scale
  • Male sex, age 15 to 49, good health
  • Willingness to have a dot tattoo placed in the target area of the scalp during the study
  • Willingness to maintain normal shampooing habits and products during the study
  • Willingness to maintain the same hair style, approximate length, and hair color throughout the study

Exclusion criteria

Exclusion Criteria:

  • Known sensitivity to the product
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
352 participants (actual)

Study arms

  • Experimental
    1

    Topical 5% minoxidil foam formulation used twice daily

    Drug: minoxidil

Interventions

  • Topical 5% minoxidil foam, BID, for sixteen weeks

    Also known as: Formula # P902942A00 vs Placebo foam (Formula # P902943A00)

06

What researchers measure

Primary outcomes

  1. Mean change in non-vellus hair count in the target region as determined by validated computer-assisted dot-mapping technique and subject ratings

    Time frame: Baseline to 16 Weeks

Secondary outcomes

  1. Visual assessment of local dermatitis

    Time frame: Each visit, Baseline through Week 16

  2. Vital Signs

    Time frame: Each visit, Baseline through Week 16

  3. Secondary efficacy evaluated by expert panel review of hair regrowth when comparing global photographs

    Time frame: Baseline vs Week 16

  4. Percent change from baseline in non-vellus hair counts within a specified area of clipped hair

    Time frame: Baseline vs Week 16

  5. Adverse Events

    Time frame: Each visit, Baseline through Week 16

  6. Laboratory Tests (hematology, chemistries, and urinalysis)

    Time frame: at Baseline, Week 8, and Week 16 and Final Visit

  7. Clinical safety assessments, including weight, blood pressure, pulse and adverse events

    Time frame: Every eight weeks, up to one year

07

Study locations

15 sites
  • Pfizer Investigational Site
    La Jolla, California 92037, United States
  • Pfizer Investigational Site
    San Francisco, California 94102, United States
  • Pfizer Investigational Site
    Vallejo, California 94503, United States
  • Pfizer Investigational Site
    Denver, Colorado 80012, United States
  • Pfizer Investigational Site
    New Haven, Connecticut 06510, United States
  • Pfizer Investigational Site
    Fridley, Minnesota 55421, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota 55401, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27701, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45202, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44101, United States
  • Pfizer Investigational Site
    Portland, Oregon 97201, United States
  • Pfizer Investigational Site
    Hershey, Pennsylvania 17033, United States
  • Pfizer Investigational Site
    Austin, Texas 78701, United States
  • Pfizer Investigational Site
    Dallas, Texas 75201, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84101, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003, a primary completion of Jul 2004 and a completion of Jul 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 9, 2005
Start
Oct 2003
Primary completionActual
Jul 2004
CompletionActual
Jul 2004
Last update
Sep 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00151515
Responsible party
Sponsor
First posted
Sep 9, 2005
Start date
Oct 2003
Primary completion
Jul 2004
Completion
Jul 2004
Last update
Sep 30, 2016

Study contacts

Bruce Kohut, DMD
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Minoxidil

Start the discussion